Faster Drug Discovery: Yseop & AWS Unveils GenAI Tool for Biopharma R&D

What You Should Know:

·      Yseop, a world-leading Artificial Intelligence (AI) software company and pioneer in Generative AI, has announced today the development of an enhanced Generative AI application tailored for the Biopharma industry, with support from Amazon Web Services (AWS).

·      A member of the AWS Partner Network (APN), Yseop has strategically utilized AWS since its inception, leveraging its robust security and scalability to enhance its Large Language Model (LLM) ecosystem, infrastructure, and technological expertise. With AWS’s backing, Yseop aims to empower leading Biopharma companies globally, facilitating the expedited delivery of pharmaceuticals and vaccines to market.

Yseop and AWS Revolutionize Biopharma with Enhanced Generative AI Application

By harnessing the capabilities of AWS, Yseop now seamlessly embeds LLM models, facilitating the generation of comprehensive scientific content while ensuring compliance with the stringent security standards of the pharmaceutical sector. This collaborative effort between AWS and Yseop enables scientific and medical writers within prominent pharmaceutical corporations to significantly augment their productivity, thereby accelerating the dissemination of therapeutics to those in need.

Miguel Alava, AWS Managing Director, Software Companies EMEA, emphasized the joint initiative between Yseop and AWS, stating, “Yseop and AWS are collaborating to democratize access to generative AI, delivering unparalleled business value to the life sciences sector while navigating challenges such as scalability and trust. Leveraging capabilities like Amazon SageMaker and Amazon Bedrock, Yseop can effectively address the rigorous AI software and data requirements prevalent across Biopharma.”

In the Biopharma domain, Yseop’s collaboration with AWS offers a multitude of advantages, including accelerating time-to-value through a pre-configured SaaS enterprise platform powered by AWS, securely scaling content generation across organizations via AWS managed services and tools such as Amazon EKS, Amazon RDS, and Infrastructure as Code CDK, managing end-to-end data and document flows with enhanced security features, and harnessing the latest AI capabilities through a model-agnostic SaaS powered by AWS SageMaker, AWS Inferentia, and AWS EC2.

Crucially, AWS provides Yseop and its clientele with a fully managed, private cloud environment, crucial for compliance within the regulated life science industry.

Yseop stands at the forefront of Generative AI for life science and pharmaceutical enterprises, revolutionizing content automation solutions with a human-centric, AI platform. Serving as a trailblazer in Natural Language Processing (NLP) technology, Yseop acts as a “Copilot” for medical writers, enhancing their efficiency and accuracy in generating pivotal reports essential for drug development and approval processes. By integrating cutting-edge language models, Yseop ensures that pharmaceutical firms effectively tackle the most demanding content tasks with ease, scalability, and utmost application security.